Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.14 USD | -1.20% | +1.53% | +49.14% |
05-03 | Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 | MT |
05-02 | Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.14% | 2.37B | |
+18.26% | 47.02B | |
+48.77% | 41.86B | |
+1.34% | 41.76B | |
-4.27% | 28.8B | |
+11.29% | 26.05B | |
-21.13% | 19.15B | |
+4.67% | 12.55B | |
+27.97% | 12.34B | |
-3.54% | 11.82B |
- Stock Market
- Equities
- KYMR Stock
- News Kymera Therapeutics, Inc.
- Piper Sandler Raises Price Target on Kymera Therapeutics to $56 From $39, Maintains Overweight Rating